Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Circulating tumor DNA (ctDNA) is an attractive source for liquid biopsy to understand molecular phenotypes of a tumor non-invasively, which is also expected to be both a diagnostic and prognostic marker. PIK3CA and KRAS are among the most frequently mutated genes in epithelial ovarian cancer (EOC). In addition, their hotspot mutations have already been identified and are ready for a highly sensitive analysis. Our aim is to clarify the significance of PIK3CA and KRAS mutations in the plasma of EOC patients as tumor-informed ctDNA. Materials and Methods We screened 306 patients with ovarian tumors for somatic PIK3CA or KRAS mutations. A total of 85 EOC patients had somatic PIK3CA and/or KRAS mutations, and the correspon-ding mutations were subsequently analyzed using a droplet digital polymerase chain reaction in their plasma. Results The detection rates for ctDNA were 27% in EOC patients. Advanced stage and positive peritoneal cytology were associated with higher frequency of ctDNA detection. Preoperative ctDNA detection was found to be an indicator of outcomes, and multivariate analysis revealed that ctDNA remained an independent risk factor for recurrence (p=0.010). Moreover, we assessed the mutation frequency in matched plasma before surgery and at recurrence from 17 patients, and found six patients had higher mutation rates in cell-free DNA at recurrence compared to that at primary diagnosis. Conclusion The presence of ctDNA at diagnosis was an indicator for recurrence, which suggests potential tumor spread even when tumors were localized at the time of diagnosis.
Abstract
Purpose Circulating tumor DNA (ctDNA) is an attractive source for liquid biopsy to understand molecular phenotypes of a tumor non-invasively, which is also expected to be both a diagnostic and prognostic marker. PIK3CA and KRAS are among the most frequently mutated genes in epithelial ovarian cancer (EOC). In addition, their hotspot mutations have already been identified and are ready for a highly sensitive analysis. Our aim is to clarify the significance of PIK3CA and KRAS mutations in the plasma of EOC patients as tumor-informed ctDNA. Materials and Methods We screened 306 patients with ovarian tumors for somatic PIK3CA or KRAS mutations. A total of 85 EOC patients had somatic PIK3CA and/or KRAS mutations, and the correspon-ding mutations were subsequently analyzed using a droplet digital polymerase chain reaction in their plasma. Results The detection rates for ctDNA were 27% in EOC patients. Advanced stage and positive peritoneal cytology were associated with higher frequency of ctDNA detection. Preoperative ctDNA detection was found to be an indicator of outcomes, and multivariate analysis revealed that ctDNA remained an independent risk factor for recurrence (p=0.010). Moreover, we assessed the mutation frequency in matched plasma before surgery and at recurrence from 17 patients, and found six patients had higher mutation rates in cell-free DNA at recurrence compared to that at primary diagnosis. Conclusion The presence of ctDNA at diagnosis was an indicator for recurrence, which suggests potential tumor spread even when tumors were localized at the time of diagnosis.
참고문헌 (27)
- Diehl F, "Circulating mutant DNA to assess tumor dynamics", Nat Med, 14, pp.985~990 (2008)
- De Roock W, "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal can-cer : a retrospective consortium analysis", Lancet Oncol, 11, pp.753~762 (2010)
- Tabernero J, "Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer : a retrospective, exploratory analysis of the CORRECT trial", Lancet Oncol, 16, pp.937~948 (2015)
- Haber DA, "Blood-based analyses of cancer : circulating tumor cells and circulating tumor DNA", Cancer Discov, 4, pp.650~661 (2014)
- Mandel P, "Article in undetermined language", C R Seances Soc Biol Fil, 142, pp.241~243 (1948)
- Offin M, "Capturing genomic evolution of lung cancers thro-ugh liquid biopsy for circulating tumor DNA", J Oncol, 2017, pp.4517834~ (2017)
- Dawson SJ, "Analysis of circulating tumor DNA to monitor metastatic breast cancer", N Engl J Med, 368, pp.1199~1209 (2013)
- Isabella Wai Yin Cheuk, "Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis", Journal of Breast Cancer, 20(1), pp.12~19 (2017), 한국유방암학회[DOI]
- Beije N, "Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases", Mol Oncol, 10, pp.1575~1584 (2016)
- Przybyl J, "Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma", Clin Cancer Res, 24, pp.2688~2699 (2018)
- Huang A, "Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity", J Cancer, 7, pp.1907~1914 (2016)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Bast RC Jr, "The biology of ovarian cancer : new opportunities for translation", Nat Rev Cancer, 9, pp.415~428 (2009)
- 김용만, "Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma", Journal of Gynecologic Oncology, 30(3), pp.1~13 (2019), 대한부인종양학회[DOI]
- Phallen J, "Direct detection of early-stage cancers using circulating tumor DNA", Sci Transl Med, 9, pp.eaan2415~ (2017)
- Morikawa A, "PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma", Oncotarget, 9, pp.15266~15274 (2018)
- Swisher EM, "Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer", Am J Obstet Gynecol, 193(3 Pt 1), pp.662~667 (2005)
- Pereira E, "Personalized circulating tumor DNA biomarkers dynamically predict treatment res-ponse and survival in gynecologic cancers", PLoS One, 10, pp.e0145754~ (2015)
- Otsuka J, "Detection of p53 mutations in the plasma DNA of patients with ovarian cancer", Int J Gynecol Cancer, 14, pp.459~464 (2004)
- Parkinson CA, "Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma : a retrospective study", PLoS Med, 13, pp.e1002198~ (2016)
- Zhuang R, "The prognostic value of KRAS mutation by cell-free DNA in cancer patients : a systematic review and meta-analysis", PLoS One, 12, pp.e0182562~ (2017)
- Barbosa A, "Potential clinical applications of circulating cell-free DNA in ovarian cancer patients", Expert Rev Mol Med, 20, pp.e6~ (2018)
- Bolivar AM, "Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA : identification of plasma-based, tumor-associated mutations in early stage patients", Mod Pathol, 32, pp.405~414 (2019)
- Scholer LV, "Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer", Clin Cancer Res, 23, pp.5437~5445 (2017)
- Iwama E, "Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations", Ann Oncol, 28, pp.136~141 (2017)
- Oshiro C, "PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients", Breast Cancer Res Treat, 150, pp.299~307 (2015)
- Pietrasz D, "Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker", Clin Cancer Res, 23, pp.116~123 (2017)